RxDoctor Payments Data

Minh le, DO

Family Medicine · Arlington, TXNPI 1629203724

Payments from drug & device makers

$10,384in general payments, 2019–2025

Across 745 payments — averaging $13.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • Pfizer$894
  • Boehringer Ingelheim$773
  • AstraZeneca$764
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$10,339100%
  • Education$450%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,384 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$97,045
Medicare patients
164
Services billed
1,484

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide93$117,828
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf13$60,141
JardianceEmpagliflozin49$54,862
MounjaroTirzepatide39$52,502
Synjardy XrEmpagliflozin/Metformin Hcl39$31,728
TrulicityDulaglutide26$27,710
FarxigaDapagliflozin Propanediol31$24,355
EliquisApixaban28$19,403
JanuviaSitagliptin Phosphate16$18,886
TradjentaLinagliptin12$9,220
LinzessLinaclotide13$9,095
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$5,717
SymbicortBudesonide/Formoterol Fumarate19$5,274
Atorvastatin Calcium417$3,338
Fluticasone Propionate168$3,062

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,190$117,82893 claims
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta$773$95,810100 claims
Lilly USA, LLCMounjaro, Trulicity$1,151$80,21265 claims
AstraZenecaFarxiga, Symbicort$764$29,63050 claims
PfizerEliquis$894$19,40328 claims
MerckJanuvia$276$18,88616 claims
AbbVieLinzess, Synthroid$1,766$10,36630 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Arlington

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →